Methods and compositions for the specific inhibition of transthyretin (ttr) by double-stranded rna
AssigneeDicerna Pharmaceuticals, Inc.
InventorsBob D. BROWN, Henryk T. DUDEK
Life of this patent
Estimating the term…
Abstract
This invention relates to compounds, compositions, and methods useful for reducing transthyretin (TTR) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
Claims86
A nucleic acid comprising an oligonucleotide strand of 15-53 nucleotides in length, wherein said oligonucleotide strand is sufficiently complementary to a target transthyretin mRNA sequence selected from SEQ ID NOs:
- 1921-2304 along at least 15 nucleotides of said oligonucleotide strand length to reduce transthyretin target mRNA expression when said nucleic acid is introduced into a mammalian cell.
A nucleic acid comprising an oligonucleotide strand of 19-53 nucleotides in length, wherein said oligonucleotide strand is sufficiently complementary to a target transthyretin mRNA sequence selected from SEQ ID NOs:
- 1921-2304 along at least 19 nucleotides of said oligonucleotide strand length to reduce transthyretin target mRNA expression when said nucleic acid is introduced into a mammalian cell.
A double stranded nucleic acid (dsNA) comprising first and second nucleic acid strands comprising RNA, wherein said first strand is 15-66 nucleotides in length and said second strand of said dsNA is 19-66 nucleotides in length, wherein said second oligonucleotide strand is sufficiently complementary to a target transthyretin mRNA sequence selected from SEQ ID NOs:
- 1921-2304 along at least 15 nucleotides of said second oligonucleotide strand length to reduce transthyretin target mRNA expression when said double stranded nucleic acid is introduced into a mammalian cell.
A double stranded nucleic acid (dsNA) comprising first and second nucleic acid strands, wherein said first strand is 15-66 nucleotides in length and said second strand of said dsNA is 19-66 nucleotides in length, wherein said second oligonucleotide strand is sufficiently complementary to a target transthyretin mRNA sequence selected from SEQ ID NOs:
- 1921-2304 along at least 19 nucleotides of said second oligonucleotide strand length to reduce transthyretin target mRNA expression when said double stranded nucleic acid is introduced into a mammalian cell.
A double stranded nucleic acid (dsNA) comprising first and second nucleic acid strands, wherein said first strand is 15-66 nucleotides in length and said second strand of said dsNA is 19-66 nucleotides in length, wherein said second oligonucleotide strand is sufficiently complementary to a target transthyretin mRNA sequence selected from SEQ ID NOs:
- 1921-2304 along at least 19 nucleotides of said second oligonucleotide strand length to reduce transthyretin target mRNA expression, and wherein, starting from the 5′ end of the transthyretin mRNA sequence selected from SEQ ID NOs:
- 1921-2304 (position 1), mammalian Ago2 cleaves said mRNA at a site between positions 9 and 10 of said sequence, when said double stranded nucleic acid is introduced into a mammalian cell.
A dsNA molecule, consisting of:
- (a) a sense region and an antisense region, wherein said sense region and said antisense region together form a duplex region consisting of 25-66 base pairs and said antisense region comprises a sequence that is the complement of a sequence selected from SEQ ID NOs:
- 1921-2304;
- and (b) from zero to two 3′ overhang regions, wherein each overhang region is six or fewer nucleotides in length, and wherein, starting from the 5′ end of the transthyretin mRNA sequence selected from SEQ ID NOs:
- 1921-2304 (position 1), mammalian Ago2 cleaves said mRNA at a site between positions 9 and 10 of said sequence, when said double stranded nucleic acid is introduced into a mammalian cell.
A double stranded nucleic acid (dsNA) comprising first and second nucleic acid strands and a duplex region of at least 25 base pairs, wherein said first strand is 25-65 nucleotides in length and said second strand of said dsNA is 26-66 nucleotides in length and comprises 1-5 single-stranded nucleotides at its 3′ terminus, wherein said second oligonucleotide strand is sufficiently complementary to a target transthyretin mRNA sequence selected from SEQ ID NOs:
- 1921-2304 along at least 19 nucleotides of said second oligonucleotide strand length to reduce transthyretin target gene expression when said double stranded nucleic acid is introduced into a mammalian cell.
A double stranded nucleic acid (dsNA) comprising first and second nucleic acid strands and a duplex region of at least 25 base pairs, wherein said first strand is 25-65 nucleotides in length and said second strand of said dsNA is 26-66 nucleotides in length and comprises 1-5 single-stranded nucleotides at its 3′ terminus, wherein the 3′ terminus of said first oligonucleotide strand and the 5′ terminus of said second oligonucleotide strand form a blunt end, and said second oligonucleotide strand is sufficiently complementary to a target transthyretin sequence selected from the group consisting of SEQ ID NOs:
- 1921-2304 along at least 19 nucleotides of said second oligonucleotide strand length to reduce transthyretin mRNA expression when said double stranded nucleic acid is introduced into a mammalian cell.
The dsNA of any one of claim 4-9 or 55, wherein said first strand is 15-35 nucleotides in length.
The dsNA of any one of claim 4-10 or 55, wherein said second strand is 19-35 nucleotides in length.
The dsNA of any of claim 4-11 or 55 comprising a duplex region selected from the group consisting of at least 25 base pairs;
- 19-21 base pairs and 21-25 base pairs.
The dsNA of any of claim 4-12 or 55, wherein said second oligonucleotide strand comprises 1-5 single-stranded nucleotides at its 3′ terminus.
The dsNA of any one of claim 4-12 or 55, wherein said second oligonucleotide strand comprises 5-35 single-stranded nucleotides at its 3′ terminus.
The nucleic acid or dsNA of any of the preceding claims or claim 55, wherein the 3′ end of the first strand and the 5′ end of the second strand are joined by a polynucleotide sequence comprising ribonucleotides, deoxyribonucleotides or both, optionally wherein the polynucleotide sequence comprises a tetraloop sequence.
The dsNA of any of claim 4-18 or 55, wherein said first strand is 25-35 nucleotides in length.
The dsNA of any of claim 4-19 or 55, wherein said second strand is 25-35 nucleotides in length.
The dsNA of any of claim 4-20 or 55, wherein said second oligonucleotide strand is complementary to target transthyretin cDNA sequence GenBank Accession No. NM_000371.3 along at most 27 nucleotides of said second oligonucleotide strand length.
The dsNA of any of claim 4-20 or 55, wherein starting from the first nucleotide (position 1) at the 3′ terminus of the first oligonucleotide strand, position 1, 2 and/or 3 is substituted with a modified nucleotide.
The dsNA of any of claim 4-20 or 55, wherein said 3′ terminus of said first strand and said 5′ terminus of said second strand form a blunt end.
The dsNA of any of claim 4-20 or 55, wherein said first strand is 25 nucleotides in length and said second strand is 27 nucleotides in length.
The dsNA of any of claim 4-5 or 7-24 or 55, wherein, starting from the 5′ end of a transthyretin mRNA sequence selected from SEQ ID NOs:
- 1921-2304 (position 1), mammalian Ago2 cleaves said mRNA at a site between positions 9 and 10 of said sequence, thereby reducing transthyretin target mRNA expression when said double stranded nucleic acid is introduced into a mammalian cell.
The dsNA of any of claim 4-25 or 55, wherein said second strand comprises a sequence selected from the group consisting of SEQ ID NOs:
- 385-768.
The dsNA of any of claim 4-26 or 55, wherein said first strand comprises a sequence selected from the group consisting of SEQ ID NOs:
- 1-384.
The dsNA of any of claim 4-27 or 55 comprising a pair of first strand/second strand sequences selected from Table 2.
The dsNA of any one of claim 4-38 or 55, wherein said second oligonucleotide strand comprises a modification pattern selected from the group consisting of AS-M1 to AS-M96 and AS-M1* to AS-M96*.
The dsNA of any one of claim 4-39 or 55, wherein said first oligonucleotide strand comprises a modification pattern selected from the group consisting of SMI to SMI 19.
The dsNA of any of claim 4-40 or 55, wherein each of said first and said second strands has a length which is at least 26 and at most 30 nucleotides.
The dsNA of any of claim 4-41 or 55, wherein said dsNA is cleaved endogenously in said cell by Dicer.
The nucleic acid, dsNA or hybridization complex of any one of the preceding claims or claim 55, wherein the amount of said nucleic acid sufficient to reduce expression of the target gene is selected from the group consisting of 1 nanomolar or less, 200 picomolar or less, 100 picomolar or less, 50 picomolar or less, 20 picomolar or less, 10 picomolar or less, 5 picomolar or less, 2, picomolar or less and 1 picomolar or less in the environment of said cell.
The dsNA of any of claim 7-43 or 55, wherein said dsNA possesses greater potency than a 21mer siRNA directed to the identical at least 19 nucleotides of said target transthyretin mRNA in reducing target transthyretin mRNA expression when assayed in vitro in a mammalian cell at an effective concentration in the environment of a cell of 1 nanomolar or less.
The nucleic acid or dsNA of any one of the preceding claims or claim 55, wherein said nucleic acid or dsNA is sufficiently complementary to the target transthyretin mRNA sequence to reduce transthyretin target mRNA expression by an amount (expressed by %) selected from the group consisting of at least 10%, at least 50%, at least 80-90%, at least 95%, at least 98%, and at least 99% when said double stranded nucleic acid is introduced into a mammalian cell.
The dsNA of any one of claim 4-45 or 55, wherein the first and second strands are joined by a chemical linker.
The double stranded nucleic acid of any one of claim 4-46 or 55, wherein said 3′ terminus of said first strand and said 5′ terminus of said second strand are joined by a chemical linker.
The double stranded nucleic acid of any one of claim 4-47 or 55, wherein a nucleotide of said second or first strand is substituted with a modified nucleotide that directs the orientation of Dicer cleavage.
The nucleic acid, dsNA or hybridization complex of any one of the preceding claims or claim 55 comprising a modified nucleotide selected from the group consisting of a deoxyribonucleotide, a dideoxyribonucleotide, an acyclonucleotide, a 3′-deoxyadenosine (cordycepin), a 3′-azido-3′-deoxythymidine (AZT), a 2′,3′-dideoxyinosine (ddI), a 2′,3′-dideoxy-3′-thiacytidine (3TC), a 2′,3′-didehydro-2′,3′-dideoxythymidine (d4T), a monophosphate nucleotide of 3′-azido-3′-deoxythymidine (AZT), a 2′,3′-dideoxy-3′-thiacytidine (3TC) and a monophosphate nucleotide of 2′,3′-didehydro-2′,3′-dideoxythymidine (d4T), a 4-thiouracil, a 5-bromouracil, a 5-iodouracil, a 5-(3-aminoallyl)-uracil, a 2′-0-alkyl ribonucleotide, a 2′-0-methyl ribonucleotide, a 2′-amino ribonucleotide, a 2′-fluoro ribonucleotide, and a locked nucleic acid.
The nucleic acid, dsNA or hybridization complex of any one of the preceding claims or claim 56 comprising a phosphate backbone modification selected from the group consisting of a phosphonate, a phosphorothioate and a phosphotriester.
The nucleic acid, dsNA or hybridization complex of any one of the preceding claims or claim 56 comprising a modification selected from the group consisting of a morpholino nucleic acid and a peptide nucleic acid (PNA).
A composition selected from the group consisting of:
- a dsNA comprising first and second nucleic acid strands, wherein said first strand is 15-35 nucleotides in length and said second strand of said dsNA is 19-35 nucleotides in length, wherein said second oligonucleotide strand is sufficiently complementary to a target transthyretin mRNA sequence selected from SEQ ID NOs:
- 1921-2304 along at least 19 nucleotides of said second oligonucleotide strand length to reduce transthyretin target mRNA expression when said double stranded nucleic acid is introduced into a mammalian cell;
- a dsNA comprising first and second nucleic acid strands, wherein said first strand is 15-35 nucleotides in length and said second strand of said dsNA is 19-35 nucleotides in length, wherein said second oligonucleotide strand is sufficiently complementary to a target
- transthyretin mRNA sequence selected from SEQ ID NOs:
- 1921-2304 along at least 19 nucleotides of said second oligonucleotide strand length to reduce transthyretin target mRNA expression, and wherein, starting from the 5′ end of the transthyretin mRNA sequence selected from SEQ ID NOs:
- 1921-2304 (position 1), mammalian Ago2 cleaves said mRNA at a site between positions 9 and 10 of said sequence, when said double stranded nucleic acid is introduced into a mammalian cell;
- a dsNA molecule, consisting of:
- (a) a sense region and an antisense region, wherein said sense region and said antisense region together form a duplex region consisting of 25-35 base pairs and said antisense region comprises a sequence that is the complement of a sequence selected from SEQ ID NOs:
- 1921-2304;
- and (b) from zero to two 3′ overhang regions, wherein each overhang region is six or fewer nucleotides in length, and wherein, starting from the 5′ end of the transthyretin mRNA sequence selected from SEQ ID NOs:
- 1921-2304 (position 1), mammalian Ago2 cleaves said mRNA at a site between positions 9 and 10 of said sequence, when said double stranded nucleic acid is introduced into a mammalian cell;
- a dsNA comprising first and second nucleic acid strands and a duplex region of at least 25 base pairs, wherein said first strand is 25-34 nucleotides in length and said second strand of said dsNA is 26-35 nucleotides in length and comprises 1-5 single-stranded nucleotides at its 3′ terminus, wherein said second oligonucleotide strand is sufficiently complementary to a target transthyretin mRNA sequence selected from SEQ ID NOs:
- 1921-2304 along at least 19 nucleotides of said second oligonucleotide strand length to reduce transthyretin target gene expression when said double stranded nucleic acid is introduced into a mammalian cell;
- a dsNA comprising first and second nucleic acid strands and a duplex region of at least 25 base pairs, wherein said first strand is 25-34 nucleotides in length and said second strand of said dsNA is 26-35 nucleotides in length and comprises 1-5 single-stranded nucleotides at its 3′ terminus, wherein the 3′ terminus of said first oligonucleotide strand and the 5′ terminus of said second oligonucleotide strand form a blunt end, and said second oligonucleotide strand is sufficiently complementary to a target transthyretin sequence selected from the group consisting of SEQ ID NOs:
- 1921-2304 along at least 19 nucleotides of said second oligonucleotide strand length to reduce transthyretin mRNA expression when said double stranded nucleic acid is introduced into a mammalian cell;
- a nucleic acid comprising an oligonucleotide strand of 19-35 nucleotides in length, wherein said oligonucleotide strand is sufficiently complementary to a target transthyretin mRNA sequence selected from SEQ ID NOs:
- 1921-2304 along at least 19 nucleotides of said oligonucleotide strand length to reduce transthyretin target mRNA expression when said nucleic acid is introduced into a mammalian cell;
- a nucleic acid comprising an oligonucleotide strand of 15-35 nucleotides in length, wherein said oligonucleotide strand is hybridizable to a target transthyretin mRNA sequence selected from the group consisting of SEQ ID NOs:
- 1921-2304 along at least 15 nucleotides of said oligonucleotide strand length;
- a dsNA comprising first and second nucleic acid strands comprising RNA, wherein said first strand is 15-35 nucleotides in length and said second strand of said dsNA is 19-35
- nucleotides in length, wherein said second oligonucleotide strand is hybridizable to a target transthyretin mRNA sequence selected from the group consisting of SEQ ID NOs:
- 1921-2304 along at least 15 nucleotides of said second oligonucleotide strand length;
- a dsNA comprising first and second nucleic acid strands comprising RNA, wherein said first strand is 15-35 nucleotides in length and said second strand of said dsNA is at least 35 nucleotides in length and optionally comprises a sequence of at least 25 nucleotides in length of SEQ ID NOs:
- 385-768, wherein said second oligonucleotide strand is sufficiently
- complementary to a target transthyretin mRNA sequence selected from SEQ ID NOs:
- 1921-2304 along at least 15 nucleotides of said second oligonucleotide strand length to reduce transthyretin target mRNA expression when said double stranded nucleic acid is introduced into a mammalian cell;
- a dsNA comprising a first oligonucleotide strand having a 5′ terminus and a 3′ terminus and a second oligonucleotide strand having a 5′ terminus and a 3′ terminus, wherein said first strand is 25 to 53 nucleotide residues in length, wherein starting from the first nucleotide (position 1) at the 5′ terminus of the first strand, positions 1 to 23 of said first strand are ribonucleotides or modified ribonucleotides;
- said second strand is 27 to 53 nucleotide residues in length and comprises 23 consecutive ribonucleotides or modified ribonucleotides that base pair with the ribonucleotides or ribonucleotides of positions 1 to 23 of said first strand to form a duplex;
- the 5′ terminus of the first strand and the 3′ terminus of the second strand form a structure selected from the group consisting of a blunt end, a 1-6 nucleotide 5′ overhang and a 1-6 nucleotide 3′ overhang;
- the 3′ terminus of said first strand and the 5′ terminus of said second strand form a structure selected from the group consisting of a blunt end, a 1-6 nucleotide 5′ overhang and a 1-6 nucleotide 3′ overhang;
- at least one of positions 24 to the 3′ terminal nucleotide residue of said first strand is a deoxyribonucleotide or modified ribonucleotide that optionally base pairs with a deoxyribonucleotide of the second strand;
- and the second strand is sufficiently complementary to a target transthyretin mRNA sequence selected from SEQ ID NOs:
- 1921-2304 along at least 15 nucleotides of the second oligonucleotide strand length to reduce transthyretin target mRNA expression when the double stranded nucleic acid is introduced into a mammalian cell;
- a dsNA comprising a first oligonucleotide strand having a 5′ terminus and a 3′ terminus and a second oligonucleotide strand having a 5′ terminus and a 3′ terminus, wherein the second strand is 27 to 53 nucleotide residues in length, wherein starting from the first nucleotide (position 1) at the 5′ terminus of the second strand, positions 1 to 23 of the second strand are ribonucleotides or modified ribonucleotides;
- the first strand is 25 to 53 nucleotide residues in length and comprises 23 consecutive ribonucleotides or modified ribonucleotides that base pair sufficiently with the ribonucleotides of positions 1 to 23 of the second strand to form a duplex;
- at least one of positions 24 to the 3′ terminal nucleotide residue of the second strand is a deoxyribonucleotide or modified ribonucleotide, optionally that base pairs with a
- deoxyribonucleotide or modified ribonucleotide of the first strand;
- and the second strand is sufficiently complementary to a target transthyretin mRNA sequence selected from SEQ ID NOs:
- 1921-2304 along at least 15 nucleotides of the second oligonucleotide strand length to reduce transthyretin target mRNA expression when the double stranded nucleic acid is introduced into a mammalian cell;
- a dsNA comprising a first oligonucleotide strand having a 5′ terminus and a 3′ terminus and a second oligonucleotide strand having a 5′ terminus and a 3′ terminus, wherein each of the 5′ termini has a 5′ terminal nucleotide and each of the 3′ termini has a 3′ terminal nucleotide, where the first strand (or the second strand) is 25-30 nucleotide residues in length, where starting from the 5′ terminal nucleotide (position 1) positions 1 to 23 of the first strand (or the second strand) include at least 8 ribonucleotides;
- the second strand (or the first strand) is 36-66 nucleotide residues in length and, starting from the 3′ terminal nucleotide, includes at least 8 ribonucleotides in the positions paired with positions 1-23 of the first strand to form a duplex;
- where at least the 3′ terminal nucleotide of the second strand (or the first strand) is unpaired with the first strand (or the second strand), and up to 6 consecutive 3′ terminal nucleotides are unpaired with the first strand (or the second strand), thereby forming a 3′ single stranded overhang of 1-6 nucleotides;
- where the 5′ terminus of the second strand (or the first strand) includes from 10-30 consecutive nucleotides which are unpaired with the first strand (or the second strand), thereby forming a 10-30 nucleotide single stranded 5′ overhang;
- where at least the first strand (or the second strand) 5′ terminal and 3′ terminal nucleotides are base paired with nucleotides of the second strand (or first strand) when the first and second strands are aligned for maximum complementarity, thereby forming a substantially duplexed region between the first and second strands;
- and the second strand is sufficiently complementary to a target RNA along at least 19 ribonucleotides of the second strand length to reduce target gene expression when the double stranded nucleic acid is introduced into a mammalian cell;
- a dsNA comprising a first oligonucleotide strand having a 5′ terminus and a 3′ terminus and a second oligonucleotide strand having a 5′ terminus and a 3′ terminus, wherein each of the 5′ termini has a 5′ terminal nucleotide and each of the 3′ termini has a 3′ terminal nucleotide, wherein the first strand is 25-35 nucleotide residues in length, wherein starting from the 5′ terminal nucleotide (position 1) positions 1 to 25 of the second strand include at least 8 ribonucleotides;
- the second strand is 30-66 nucleotide residues in length and, starting from the 3′ terminal nucleotide, comprises at least 8 ribonucleotides in the positions paired with positions 1-25 of the first strand to form a duplex;
- wherein the 5′ terminus of the second strand comprises from 5-35 consecutive nucleotides which are unpaired with the first strand, thereby forming a 5-35 nucleotide single stranded 5′ overhang;
- wherein at least the first strand 5′ terminal and 3′ terminal nucleotides are base paired with nucleotides of the second strand when the first and second strands are aligned for maximum complementarity, thereby forming a substantially duplexed region between the first and second strands;
- and the second strand is sufficiently complementary to a target transthyretin mRNA sequence selected from SEQ ID NOs:
- 1921-2304 along at least 15 nucleotides of the second oligonucleotide strand length to reduce transthyretin target mRNA expression when the double stranded nucleic acid is introduced into a mammalian cell;
- a dsNA comprising a first oligonucleotide strand having a 5′ terminus and a 3′ terminus and a second oligonucleotide strand having a 5′ terminus and a 3′ terminus, wherein each of the 5′ termini has a 5′ terminal nucleotide and each of the 3′ termini has a 3′ terminal nucleotide, wherein the second strand is 19-30 nucleotide residues in length and optionally 25-30 nucleotide residues in length, wherein starting from the 5′ terminal nucleotide (position 1) positions 1 to 17 (optionally positions 1 to 23) of the second strand include at least 8 ribonucleotides;
- the first strand is 24-66 nucleotide residues in length (optionally 30-66 nucleotide residues in length) and, starting from the 3′ terminal nucleotide, comprises at least 8 ribonucleotides in the positions paired with positions 1 to 17 (optionally positions 1 to 23) of the second strand to form a duplex;
- wherein the 3′ terminus of the first strand and the 5′ terminus of the second strand comprise a structure selected from the group consisting of a blunt end, a 3′ overhang and a 5′ overhang, optionally wherein the overhang is 1-6 nucleotides in length;
- wherein the 5′ terminus of the first strand comprises from 5-35 consecutive nucleotides which are unpaired with the second strand, thereby forming a 5-35 nucleotide single-stranded 5′ overhang;
- where at least the second strand 5′ terminal and 3′ terminal nucleotides are base paired with nucleotides of the first strand when the first and second strands are aligned for maximum complementarity, thereby forming a substantially duplexed region between the first and second strands;
- and the second strand is sufficiently complementary to a target transthyretin mRNA sequence selected from SEQ ID NOs:
- 1921-2304 along at least 15 nucleotides of the second oligonucleotide strand length to reduce transthyretin target mRNA expression when the double stranded nucleic acid is introduced into a mammalian cell;
- a dsNA comprising a first strand and a second strand, wherein the first strand and the second strand form a duplex region of 19-25 nucleotides in length, wherein the first strand comprises a 3′ region that extends beyond the first strand-second strand duplex region and comprises a tetraloop, and the dsNA further comprises a discontinuity between the 3′ terminus of the first strand and the 5′ terminus of the second strand, and the first or second strand is sufficiently complementary to a target transthyretin mRNA sequence selected from SEQ ID NOs:
- 1921-2304 along at least 15 nucleotides of the first or second strand length to reduce transthyretin target mRNA expression when the dsNA is introduced into a mammalian cell;
- a dsNA comprising a first oligonucleotide strand having a 5′ terminus and a 3′ terminus and a second oligonucleotide strand having a 5′ terminus and a 3′ terminus, wherein each of the 5′ termini has a 5′ terminal nucleotide and each of the 3′ termini has a 3′ terminal nucleotide, wherein the first oligonucleotide strand is 25-53 nucleotides in length and the second is oligonucleotide strand is 25-53 nucleotides in length, and wherein the dsNA is sufficiently highly modified to substantially prevent dicer cleavage of the dsNA, optionally wherein the dsNA is cleaved by non-dicer nucleases to yield one or more 19-23 nucleotide strand length dsNAs capable of reducing LDH mRNA expression in a mammalian cell;
- an in vivo hybridization complex within a cell of an exogenous nucleic acid sequence and a target Transthyretin mRNA sequence selected from the group consisting of SEQ ID NOs:
- 1921-2304;
- and
- an in vitro hybridization complex within a cell of an exogenous nucleic acid sequence and a target Transthyretin mRNA sequence selected from the group consisting of SEQ ID NOs:
- 1921-2304.
A method for reducing expression of a target transthyretin gene in a mammalian cell comprising contacting a mammalian cell in vitro with a nucleic acid, dsNA or hybridization complex of any of the preceding claims in an amount sufficient to reduce expression of a target transthyretin mRNA in said cell.
Dependencies are inferred from the claim text.